Coronary/Structural Heart

CHF Solutions and RenalSense Enter Distribution Partnership to Offer Ultrafiltration and Real-Time Renal Diagnostics

EDEN PRAIRIE, Minn., July 08, 2020 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS) and RenalSense, Ltd., today announced the signing of a distribution agreement to offer complementary solutions for fluid management. The agreement allows CHF Solutions to market and sell RenalSense’s Clarity RMS™ (real-time monitoring system) in certain U.S. territories.  Clarity RMS is […]

ViralClear Pharmaceuticals partners with Albany Molecular Research Inc. on the manufacture of merimepodib active pharmaceutical ingredient development for the potential treatment of COVID-19

Westport, CT, July 08, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its subsidiary, ViralClear Pharmaceuticals, Inc., today announced that it is partnering with Albany Molecular Research Inc., (AMRI), a leading global contract research, development and manufacturing organization (CDMO), for support in undertaking research to […]

SINOMED® Completes Last Patient Follow-Up of the PIONEER-III Pivotal US and Japanese Trial of the BuMA Supreme® Coronary Drug-Eluting Stent

TIANJIN, China, July 6, 2020 /PRNewswire/ — SINOMED, a developer of innovative neuro- and cardiovascular technologies, announced the completion of the 1-year follow-up in the PIONEER-III, randomized global trial evaluating the BuMA Supreme Drug-Eluting Coronary Stent (DES). Once completed, the company plans to submit the data to the U.S. Food and Drug Administration and Japanese Pharmaceuticals […]

Paragonix Technologies Announces Utilization of Paragonix SherpaPak CTS in Complex Heart Transplant Study

New data on successful transplantations for high-risk profile donor hearts presented at the American Transplant Congress CAMBRIDGE, Mass.–(BUSINESS WIRE)–Paragonix Technologies, Inc. announced the presentation of new clinical data at the American Transplant Congress (ATC) on the successful use of the Paragonix SherpaPak™ Cardiac Transport System (CTS) for high-risk donor hearts at the […]

SARS-CoV-2 Cell Entry Mechanisms in Intact Human Heart Published in JACC: Basic to Translational Science by University of Colorado Anschutz Medical Campus and ARCA biopharma Investigators

Integrin A5 may be a new target for intervening in the cell infectious process Findings may lead to the development of precision therapeutic approaches to prevent SARS-CoV-2-cell entry while preserving the functional activity of ACE2 WESTMINSTER and AURORA, Colo., July 07, 2020 (GLOBE NEWSWIRE) — The University of Colorado Anschutz Medical […]

Celixir provides update on ongoing clinical programme with lead therapeutic candidate CLXR-001

Celixir provides update on ongoing clinical programme with lead therapeutic candidate CLXR-001 First patient successfully dosed in cardiomyopathy study Stratford-upon-Avon, UK: July, 6 2019 – Celixir, a privately-owned company discovering and developing life-saving advanced therapies, announces an update to its ongoing clinical programme with lead therapeutic candidate CLXR-001. The first patient was […]

Carag Receives U.S. FDA IDE Approval to Conduct Clinical Study of First Transcatheter Septal Occluder With Bioresorbable, Metal-free Framework

The U.S. trial for CE-marked CBSO is designed to enroll up to 250 patients in a staged study approach BAAR, Switzerland, July 1, 2020 /PRNewswire/ — CARAG AG, a privately-held Swiss medical device development company, today announced receiving U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) approval for its Carag Bioresorbable […]

Berlin Heart Completes Post Approval Surveillance; Report Details Improved Outcomes for Pediatric Heart Failure Patients Supported with EXCOR® Pediatric

THE WOODLANDS, Texas–(BUSINESS WIRE)–Berlin Heart Inc. announced they have completed the Post Approval Surveillance for the EXCOR® Pediatric Ventricular Assist Device, a requirement of the Post Market Approval (PMA) granted by the Food and Drug Administration (FDA), in June 2017. The final report submitted to the FDA confirmed the positive contemporary […]

Study Finds 84% Survival Rate in Patients in Cardiogenic Shock and Other Challenging Cardiac Conditions with the New Impella 5.5 with SmartAssist

DANVERS, Mass.–(BUSINESS WIRE)–The first published United States experience of patients who received Abiomed’s newest heart pump, Impella 5.5 with SmartAssist, finds 84% of the patients survived to explant with 76% native heart recovery. The study was published in the July edition of the American Society for Artificial Internal Organs (ASAIO) Journal. The study examined […]

Esperion Announces Publication in the Journal of the American Medical Association Cardiology of Pooled Efficacy Analysis from the Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL® (bempedoic acid) Tablets

ANN ARBOR, Mich., July 01, 2020 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that pooled efficacy analysis from the four Phase 3 clinical studies of NEXLETOL, an oral, once-daily LDL-cholesterol lowering medicine, was published in the Journal of the American Medical Association (JAMA) Cardiology.  The four Phase 3 clinical studies […]